ライフサイエンスコーパス: topiramate

1 , tiagabine, valproic acid, lamotrigine, and topiramate).

2 peptide 1 receptor agonists and phentermine-topiramate).

3 tide), bupropion-naltrexone, and phentermine-topiramate).

4 (HR, 1.65; 95% CI, 1.25-2.19), compared with topiramate.

5 riety of therapies, including gabapentin and topiramate.

6 anged from 7.3% for lamotrigine to 18.5% for topiramate.

7 , gabapentin, lamotrigine, oxcarbazepine, or topiramate.

8 ings for baclofen, modafinil, tiagabine, and topiramate.

9 , namely baclofen, modafinil, tiagabine, and topiramate.

10 sm underlying the anticonvulsant activity of topiramate.

11 tes: felbamate, gabapentin, lamotrigine, and topiramate.

12 tin, lamotrigine, felbamate, vigabatrin, and topiramate.

13 ts include verapamil, lithium, melatonin and topiramate.

14 time-by-treatment interaction, which favored topiramate.

15 sight threatening ocular adverse effects of Topiramate.

16 more than 5 times higher in patients taking topiramate.

17 tyle counseling and top-dose phentermine and topiramate.

18 ained compared with top-dose phentermine and topiramate.

19 r bupropion and 2.59 (95% CI, 1.56-4.30) for topiramate.

20 Some participants were intolerant of topiramate.

21 bupropion and 5.30 (95% CI, 2.54-11.04) for topiramate.

22 t significantly increased for acamprosate or topiramate.

23 648 randomly matched patients who never took topiramate.

24 he risk of glaucoma with first-time users of topiramate.

25 , gabapentin, lamotrigine, oxcarbazepine, or topiramate.

26 3-0.97]), gabapentin (0.65 [0.52-0.80]), and topiramate (0.64 [0.52-0.79]), and had a non-significant

27 pine against lamotrigine (0.91 [0.77-1.09]), topiramate (0.86 [0.72-1.03]), and oxcarbazepine (0.92 [

28 -0.53 (0.14) mug/L/mg (P < .001) except for topiramate (-0.35 [0.20] mug/L/mg per week) and carbamaz

29 The marketed drug topiramate ( 1) is a moderate inhibitor of carbonic anhy

30 Topiramate (1) and its sulfamide analogue 4, and 4,5-cyc

31 he clinically efficacious antiepileptic drug topiramate (1), a unique sugar sulfamate anticonvulsant

32 conformation, were nearly twice as potent as topiramate (1).

33 than both lamotrigine (1.55 [1.07-2.24] and topiramate (1.89 [1.32-2.70]).

34 r 15 mg phentermine/92 mg controlled-release topiramate (15/92)] to complete a total of 108 wk.

35 (1 mg per kilogram of body weight per day), topiramate (2 mg per kilogram per day), and placebo in c

36 6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and

37 interval [CI], 0.56 to 1.65) for exposure to topiramate, 2.67 (95% CI, 1.69 to 4.20) for exposure to

38 46%), duloxetine (30%), carbamazepine (26%), topiramate (25%), pregabalin and gabapentin (10%).

39 ramate, although a decrease was observed for topiramate (29.83 mug/L/mg to 13.77 mug/L/mg; P = .18).

40 ine (5.4%; 95% CI, 4.5%-6.4%), 10 of 204 for topiramate (4.9%; 95% CI, 2.7%-8.8%), 110 of 3584 for la

41 8.0; p<0.0001) with phentermine 7.5 mg plus topiramate 46.0 mg, and 687 (70%; 9.0, 7.3 to 11.1; p<0.

42 placebo, 19 (4%) to phentermine 7.5 mg plus topiramate 46.0 mg, and 73 (7%) to phentermine 15.0 mg p

43 d to placebo, 498 to phentermine 7.5 mg plus topiramate 46.0 mg, and 995 to phentermine 15.0 mg plus

44 assigned to placebo, phentermine 7.5 mg plus topiramate 46.0 mg, and phentermine 15.0 mg plus topiram

45 assigned to placebo, phentermine 7.5 mg plus topiramate 46.0 mg, and phentermine 15.0 mg plus topiram

46 placebo, once-daily phentermine 7.5 mg plus topiramate 46.0 mg, or once-daily phentermine 15.0 mg pl

47 ts meeting entry criteria were randomized to topiramate (50, 100, or 200 mg/d) or placebo.

48 Frequently reported drugs included topiramate (520 reports) and citalopram (69 reports), am

49 7.5 mg phentermine/46 mg controlled-release topiramate (7.5/46), or 15 mg phentermine/92 mg controll

50 compared with placebo at 1 year-phentermine-topiramate, 8.8 kg (95% CrI, -10.20 to -7.42 kg); liragl

51 aHR, 3.5; 95% CI, 1.5-8.2; lamotrigine with topiramate: 8-year cumulative incidence, 7.5%; aHR, 2.4;

52 mg, and 73 (7%) to phentermine 15.0 mg plus topiramate 92.0 mg had depression-related adverse events

53 0 mg, or once-daily phentermine 15.0 mg plus topiramate 92.0 mg in a 2:1:2 ratio in 93 centres in the

54 ramate 46.0 mg, and phentermine 15.0 mg plus topiramate 92.0 mg, respectively), paraesthesia (20 [2%]

55 ramate 46.0 mg, and phentermine 15.0 mg plus topiramate 92.0 mg, respectively.

56 46.0 mg, and 995 to phentermine 15.0 mg plus topiramate 92.0 mg; 979, 488, and 981 patients, respecti

57 1.1; p<0.0001) with phentermine 15.0 mg plus topiramate 92.0 mg; for >/=10% weight loss, the correspo

58 94%, placebo: 46%) and binge day frequency (topiramate: 93%, placebo: 46%) and with a significantly

59 antly greater reductions in binge frequency (topiramate: 94%, placebo: 46%) and binge day frequency (

60 Topiramate, a fructopyranose derivative, was superior to

61 natal seizures, we evaluated the efficacy of topiramate, a structurally novel anticonvulsant drug rec

62 Topiramate, a sulphamate fructopyranose derivative, migh

63 of the mesocorticolimbic dopamine system by topiramate-a glutamate receptor antagonist and gamma-ami

64 The results indicate that administration of topiramate after experimental status epilepticus can att

65 An urgent cessation of topiramate along with topical and systemic steroids is r

66 Patients receiving topiramate also had lower concentrations of the liver en

67 er forms of cognitive behavioral therapy and topiramate also increased abstinence and reduced binge-e

68 Topiramate also partially depressed predominantly AMPA-r

69 Topiramate also was associated, significantly more than

70 bamazepine, carbamazepine-10,11-epoxide, and topiramate, although a decrease was observed for topiram

71 We hypothesized that topiramate, an anticonvulsant with multiple mechanisms o

72 ver time, with phenobarbital, levetiracetam, topiramate and adrenocorticotropic hormone effective in

73 k has suggested efficacy and tolerability of topiramate and fluphenazine, but more rigorous studies a

74 tention (P < 0.001); among second-line ASMs, topiramate and lacosamide were both superior to zonisami

75 association was substantially attenuated for topiramate and lamotrigine, whereas an increased risk re

76 ecific psychiatric disorders associated with topiramate and levetiracetam.

77 Phentermine-topiramate and liraglutide were associated with the high

78 Valproate is better tolerated than topiramate and more efficacious than lamotrigine, and sh

79 to examine the comparative effectiveness of topiramate and naltrexone in improving outcomes in AUD a

80 2407 and rs1799971) clinical trial comparing topiramate and naltrexone in treating AUD, 147 patients

81 ither rs2832407 nor rs1799971 had effects on topiramate and naltrexone treatments, respectively.

82 IK1) and rs1799971 (in OPRM1)-on response to topiramate and naltrexone, respectively.

83 Centrally acting drugs, such as phentermine-topiramate and naltrexone-bupropion, regulate appetite i

84 Cyclic sulfate 2, like topiramate and phenytoin, did not interfere with seizure

85 rolled 12-week clinical trial comparing oral topiramate and placebo for treatment of 150 individuals

86 meta-analysis of randomized clinical trials, topiramate and pregabalin were associated with reduction

87 ong individual anticonvulsants compared with topiramate and secondarily carbamazepine.

88 ore and were less effective than phentermine-topiramate and semaglutide, respectively.

89 Newer medical treatment options like topiramate and surgical treatment options like stereotac

90 gle closure were considered to be induced by Topiramate and the drug was discontinued.

91 Topiramate and trazodone have limited evidence supportin

92 pared initiating treatment with lamotrigine, topiramate and valproate in patients diagnosed with gene

93 children of mothers with epilepsy exposed to topiramate and valproate monotherapy, 4.3% and 2.7%, res

94 .001), while lacosamide remained superior to topiramate and zonisamide for retention (P < 0.002); amo

95 xetine, 5 studies of bupropion, 9 studies of topiramate, and 1 study each of sertraline and zonisamid

96 Ondansetron, naltrexone, topiramate, and baclofen are examples.

97 Three other drugs, bupropion, topiramate, and ciliary neurotrophic factor, are undergo

98 orcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide, compared with placebo, were

99 Lamotrigine, gabapentin, topiramate, and oxcarbazepine are available for use as m

100 tide; in the USA, lorcaserin and phentermine/topiramate are also available.

101 Lamotrigine and topiramate are also thought to possess broad spectrum ac

102 ol, the beta-blocker, and the anticonvulsant topiramate are effective for migraine prevention.

103 utide, naltrexone/bupropion, and phentermine/topiramate are new agents that have been recently approv

104 Both bupropion and topiramate are widely prescribed drugs.

105 The importance of topiramate as a cause of secondary angle closure has rec

106 DESIGN, SETTING, AND PARTICIPANTS: Topiramate as a Disease-Modifying Therapy for CSPN (TopC

107 cents with obesity, top-dose phentermine and topiramate as adjunct to lifestyle counseling was estima

108 included both well-known medications such as topiramate as well as lesser-known medications such as o

109 (P<.05) occurred within the first month with topiramate at 100 and 200 mg/d.

110 creased significantly for patients receiving topiramate at 100 mg/d (-2.1, P =.008) and topiramate at

111 toneal injections of either vehicle (n=6) or topiramate at 20 mg/kg (n=6), 40 mg/kg (n=7) or 80 mg/kg

112 g topiramate at 100 mg/d (-2.1, P =.008) and topiramate at 200 mg/d (-2.4, P<.001) vs placebo (-1.1).

113 esponder rate was significantly greater with topiramate at 50 mg/d (39%, P =.01), 100 mg/d (49%, P<.0

114 Weight loss due to topiramate at 6 months was 6.5% (CI, 4.8% to 8.3%) of pr

115 These findings support the use of topiramate at a daily dose of 200 mg to reduce heavy dri

116 Administration of topiramate at each dose was associated with a significan

117 pal neurons of the rat basolateral amygdala, topiramate at low concentrations (IC50, approximately 0.

118 not cost-effective compared with phentermine-topiramate at the willingness-to-pay threshold of $100 0

119 We further demonstrate that topiramate attenuates AMPA-kainate receptor-mediated cel

120 ns with children of mothers who discontinued topiramate before pregnancy (AHR, 1.19; 95% CI, 0.26-5.4

121 nts who received their first prescription of topiramate between 2001 and 2007.

122 domly assigned to valproate, lamotrigine, or topiramate between Jan 12, 1999, and Aug 31, 2004, and f

123 f lamotrigine, levetiracetam, oxcarbazepine, topiramate, brivaracetam, zonisamide, or pregabalin.

124 medications, including orlistat, phentermine-topiramate, bupropion-naltrexone, or setmelanotide.

125 bypass were more effective than phentermine-topiramate but were also more costly, rendering them not

126 was also decreased by the antiepileptic drug topiramate, but not by carbamazepine.

127 Hypothetically, topiramate can improve drinking outcomes among alcohol-d

128 The combination of phentermine and topiramate caused significant weight loss, slowed gastri

129 However, there is limited literature on Topiramate causing hypopyon uveitis and intense ocular i

130 tricyclic antidepressants, anticonvulsants (topiramate), coenzyme Q-10, and L-carnitine.

131 cified mixed-model analysis also showed that topiramate compared with placebo decreased the percentag

132 d over the course of double-blind treatment, topiramate, compared with placebo, improved the odds of

133 At study end, participants on topiramate, compared with those on placebo, had 2.88 (95

134 mood stabilizers, whereas carbamazepine and topiramate continued to produce positive results, olanza

135 and safety of two doses of phentermine plus topiramate controlled-release combination as an adjunct

136 Topiramate did not alter the degree of facilitation in p

137 dinal analyses showed that amitriptyline and topiramate did not explain intercept random effects for

138 raines (<15 headaches per month) included topiramate (difference in headaches per month, -0.71; 95

139 patients (three receiving placebo, six given topiramate) discontinued because of adverse events.

140 use of several antiepileptic agents such as topiramate, disodium valproate, levetiracetam, the antih

141 Notably, protective doses of NBQX and topiramate do not affect normal maturation and prolifera

142 Median topiramate dose was 212 mg/day (range=50-600).

143 to the side of stimulation at the two higher topiramate doses only.

144 weeks to a maximum dose of 60 mg daily, and topiramate doses were titrated over 6 weeks to a maximum

145 , in animals that had seizures suppressed by topiramate during acute hypoxia, there were no long-term

146 Children who had been exposed to topiramate during the second half of pregnancy were comp

147 Topiramate effectively suppressed acute seizures induced

148 s, such as carbamazepine, oxcarbazepine, and topiramate, enhances hepatic cytochrome P450 3A4 (CYP3A4

149 Seventy-five participants received topiramate (escalating dose of 25 mg/d to 300 mg/d), and

150 150 individuals, 75 were assigned to receive topiramate (escalating dose of 25-300 mg per day) and 75

151 tyline: estimate [SE], 0.25 [0.38]; P = .52; topiramate: estimate [SE], -0.09 [0.39]; P = .82) change

152 tyline: estimate [SE], 0.07 [0.05]; P = .16; topiramate: estimate [SE], 0.04 [0.05]; P = .50) or head

153 The aHRs for ASD and ID after topiramate exposure were 2.8 (95% CI, 1.4-5.7) and 3.5 (

154 tide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate extended-release (ER), naltrexone-bupropion E

155 9% for top-dose (15/92 mg) phentermine plus topiramate-extended release at 1 year.

156 and 67% to 70% for top-dose phentermine plus topiramate-extended release.

157 rbital, phenytoin, primidone, rufinamide, or topiramate) following an adult-onset (age 18 years) epil

158 extended-release mixed amphetamine salts and topiramate group (33.3%) than in placebo group (16.7%).

159 omly assigned to treatment groups: 66 in the topiramate group and 66 in the placebo group.

160 Although IENFD was stable in the topiramate group compared with a decline consistent with

161 ents of altered mood, and one patient in the topiramate group had a suicide attempt.

162 PTSD scores were lower in the PE+topiramate group than in the PE+placebo group at posttre

163 the amitriptyline group, 55% of those in the topiramate group, and 61% of those in the placebo group

164 (132 in the amitriptyline group, 130 in the topiramate group, and 66 in the placebo group).

165 % vs. 8%) and weight loss (8% vs. 0%) in the topiramate group.

166 e events resulting in discontinuation in the topiramate groups included paresthesia, fatigue, and nau

167 the 100-mg/d (P =.01) and 200-mg/d (P =.005) topiramate groups.

168 the 100-mg/d (P =.003) and 200-mg/d (P<.001) topiramate groups.

169 Patients treated with topiramate had a mean (SD) annual change in IENFD of 0.5

170 ad lower all-cause discontinuation; however, topiramate had higher all-cause discontinuation (N = 70,

171 Patients who received amitriptyline or topiramate had higher rates of several adverse events th

172 and oxcarbazepine for retention (P < 0.02); topiramate had the best seizure freedom among second-lin

173 Semaglutide and phentermine/topiramate had the largest effects on BMI (eg, 1 RCT [n

174 Topiramate has been shown to reduce drinking and heavy d

175 Amphetamine and topiramate have both shown promise for the treatment of

176 nded release combination of phentermine with topiramate have recently gained approval.

177 ure, valproate was significantly better than topiramate (hazard ratio 1.57 [95% CI 1.19-2.08]), but t

178 day: WMD, -1.02; 95% CI, -1.77 to -0.28) and topiramate (% heavy drinking days: WMD, -9.0%; 95% CI, -

179 re supported with low-confidence data (e.g., topiramate, histamine-2 receptor antagonists).

180 Testing the approach with valproate and topiramate identified expected signals and a signal for

181 ed trial of extended-release phentermine and topiramate in 24 patients to validate associations betwe

182 significant difference between valproate and topiramate in either the analysis overall or for the sub

183 s evaluated the efficacy and tolerability of topiramate in heavy drinkers whose treatment goal was to

184 The objective of this study was to evaluate topiramate in the treatment of binge eating disorder ass

185 as liraglutide, semaglutide, and phentermine/topiramate, in combination with lifestyle modification t

186 Topiramate-induced differences in craving were also sign

187 Topiramate is a promising treatment for alcohol dependen

188 To determine if topiramate is a safe and efficacious treatment for alcoh

189 Topiramate is a widely used antiepileptic agent whose me

190 Topiramate is an antiepileptic agent associated with wei

191 that the mechanism of protective efficacy of topiramate is caused at least in part by attenuation of

192 d trials suggest that the antiepileptic drug topiramate is effective for migraine prevention.

193 The anticonvulsant topiramate is effective for migraine prevention.

194 evidence that the combination of MAS-ER and topiramate is efficacious in promoting abstinence in coc

195 Topiramate is more efficacious than placebo at increasin

196 soflurane, desflurane), antiepileptic drugs (topiramate, lacosamide, pregabalin, levetiracetam), hypo

197 The addition of topiramate led to more rapid and pronounced PTSD symptom

198 ing noncompliant participants based on serum topiramate levels and those with major protocol deviatio

199 Patients were randomized to receive either topiramate (maximal daily dosage of 200 mg/day) or place

200 Our results suggest that topiramate may have clinical potential as a therapeutic

201 ticholinergics, certain antidepressants, and topiramate may predispose patients to glaucoma.

202 ine, and tiagabine, compared with the use of topiramate, may be associated with an increased risk of

203 Age and sex were similar between groups (topiramate: mean [SD] age, 61 (10) years; 38 male [58%];

204 Prenatal exposure to topiramate monotherapy was associated with increased ris

205 Analyses compared the topiramate (n = 12) and placebo (n = 8) groups on (1) th

206 Up to 300 mg/d of topiramate (n = 183) or placebo (n = 188), along with a

207 Topiramate (n = 71) or placebo (n = 71) in escalating do

208 0 kg/m(2)) were randomly assigned to receive topiramate (N=30) or placebo (N=31).

209 signed to receive 12 weeks of treatment with topiramate (N=67), at a maximal daily dose of 200 mg, or

210 opic polypeptide/GLP-1 agonist), phentermine-topiramate, naltrexone-bupropion, and orlistat.

211 anagement (orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide, 3.0 m

212 t, and 2 studies compared different doses of topiramate; none of these trials showed significant diff

213 ss vs 75% of participants taking phentermine-topiramate (odds ratio [OR], 9.22; 95% credible interval

214 Topiramate, onabotulinum toxin type A, gabapentin, petas

215 at longer-term follow-up, extending time on topiramate or additional strategies to prolong such effe

216 Participants received topiramate or matched placebo titrated to a maximum-tole

217 AUD were randomly assigned to treatment with topiramate or naltrexone, stratified by genotype (rs2832

218 release mixed amphetamine salts (MAS-ER) and topiramate or placebo for 12 weeks under double-blind co

219 lfiram, acamprosate, naltrexone, gabapentin, topiramate, or baclofen.

220 oxy-6-nitro-7-sulfonyl-benzo[f]quinoxaline), topiramate, or GYKI-53773 [(1)-1-(4-aminophenyl)-3-acety

221 and adolescent migraine with amitriptyline, topiramate, or placebo over a period of 24 weeks.

222 ch randomized participants to amitriptyline, topiramate, or placebo.

223 ine and topiramate, top-dose phentermine and topiramate, or semaglutide over 13 months, 2 years, and

224 ine and topiramate, top-dose phentermine and topiramate, or semaglutide.

225 < 0.001) but lower seizure freedom rate than topiramate (P = 0.032); among third-line ASMs, cenobamat

226 amate vs. placebo, P=0.48; amitriptyline vs. topiramate, P=0.49).

227 Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle mod

228 ted rate ratios were computed for bupropion, topiramate (positive control group drug), and esomeprazo

229 propion, bupropion, probably fluoxetine, and topiramate promote modest weight loss when given along w

230 avioral therapy, lisdexamfetamine, SGAs, and topiramate reduced binge eating and related psychopathol

231 In a prior study, topiramate reduced heavy drinking among individuals who

232 Topiramate reduced weight and increased sympathetic nerv

233 ed psychopathology, and lisdexamfetamine and topiramate reduced weight in adults with binge-eating di

234 cinnarizine (RoM, 0.64; 95% CI, 0.46-0.88), topiramate (RoM, 0.70; 95% CI, 0.55-0.89), and amitripty

235 the risk of glaucoma among current users of topiramate (RR = 1.23 [95% confidence interval (CI), 1.0

236 mitriptyline (RR, 3.81; 95% CI, 1.41-10.32), topiramate (RR, 4.34; 95% CI, 1.60-11.75), and valproate

237 In a European American subsample (N=122), topiramate's effect on heavy drinking days was significa

238 ate the kainate receptor in the mechanism of topiramate's effects on heavy drinking.

239 Phentermine-topiramate seems to have the highest weight loss potenti

240 Topiramate showed significant efficacy in migraine preve

241 erence [SMD], -0.20; 95% CI, -0.91 to 0.31), topiramate (SMD, 0.20; 95% CI, -0.36 to 0.76), or amitri

242 ts with severe obesity, we found phentermine-topiramate to be a cost-effective treatment at a willing

243 nct to liraglutide, mid-dose phentermine and topiramate, top-dose phentermine and topiramate, or sema

244 nct to liraglutide, mid-dose phentermine and topiramate, top-dose phentermine and topiramate, or sema

245 Topiramate (Topamax) and phentermine have long been appr

246 valproate (VPA) 0.74 (0.10 to 1.38) p=0.02; topiramate (TPM) -2.30 (-4.27 to -0.33) p=0.02.

247 It was hypothesized that topiramate-treated patients would be better able to achi

248 The mean weight loss for topiramate-treated subjects who completed the study was

249 y drinkers who are likely to respond well to topiramate treatment and provide an important personaliz

250 Topiramate treatment significantly reduced heavy drinkin

251 f they had poorly controlled diabetes, prior topiramate treatment, recurrent nephrolithiasis, type 1

252 s showing a reduction in heavy drinking with topiramate treatment, the prior finding of a moderating

253 double-blind, flexible-dose (25-600 mg/day) topiramate trial, 61 outpatients (53 women, eight men) w

254 refractory to medications at the time of the topiramate trial, possibly explaining this isolated diff

255 ly assigned to 16 weeks of treatment with PE+topiramate (up to 250 mg) or PE+placebo to examine effec

256 Topiramate (up to 300 mg per day) is more efficacious th

257 medication compliance enhancement treatment, topiramate (up to 300 mg/d) was superior to placebo at n

258 Topiramate use in Taiwan was associated with a significa

259 m spectrum disorder associated with maternal topiramate use.

260 ring drug therapy was observed among current topiramate users (RR = 1.09 [95% CI, 0.80-1.61]).

261 idal anti-inflammatory drugs, beta-blockers, topiramate, valproate, and antidepressants.

262 In this cohort study, prenatal exposure to topiramate, valproate, and several duotherapies were ass

263 the consensus effectiveness of lamotrigine, topiramate, valproate, aripiprazole, olanzapine, and ome

264 Risk of autism after prenatal topiramate, valproate, or lamotrigine exposure.

265 Topiramate, valproate, propranolol, amitriptyline, and m

266 ntin, lamotrigine, levetiracetam, tiagabine, topiramate, vigabatrin, and zonisamide do not induce the

267 abapentin vs carbamazepine, 0.71, 0.59-0.86; topiramate vs carbamazepine, 0.81, 0.68-0.98).

268 t, liraglutide, semaglutide, and phentermine-topiramate vs no treatment.

269 Adverse events that were more common with topiramate vs placebo, respectively, included paresthesi

270 bo group (amitriptyline vs. placebo, P=0.26; topiramate vs. placebo, P=0.48; amitriptyline vs. topira

271 Topiramate was also associated with significantly greate

272 ls [RCTs]; 16 964 participants), phentermine-topiramate was associated with 8.0% greater weight loss

273 PE+topiramate was associated with a greater reduction in PT

274 Compared with placebo, topiramate was associated with a significantly greater r

275 es of dry mouth, headache, and insomnia, and topiramate was associated with higher rates of paresthes

276 Topiramate was efficacious and relatively well tolerated

277 In the meta-analysis of the pooled data, topiramate was found to be significantly more effective

278 We aimed to see whether topiramate was more effective than placebo as a treatmen

279 Using an intent-to-treat analysis, topiramate was more efficacious than placebo at increasi

280 reating all dropouts as relapse to baseline, topiramate was more efficacious than placebo at reducing

281 At 5 years, top-dose phentermine and topiramate was projected to be the preferred strategy wi

282 The anticonvulsant topiramate was recently shown to be effective for migrai

283 ; weight loss in response to phentermine and topiramate was significantly associated with calorie int

284 ntly approved for pediatric use, phentermine-topiramate was the most cost-effective with an increment

285 Topiramate was titrated by 25 mg/wk for 8 weeks to the a

286 DA-approved MAUDs (baclofen, gabapentin, and topiramate) was determined.

287 Additionally, children exposed to topiramate were 2.5 times more likely to be diagnosed wi

288 etam with carbamazepine and lamotrigine with topiramate were associated with increased risks of neuro

289 ate ratios (RRs) for current and past use of topiramate were computed.

290 ons; guided self-help, lisdexamfetamine, and topiramate were effective for reducing eating disorder s

291 ial confounding factors, patients prescribed topiramate were found to have a 7.41-fold (95% confidenc

292 The most common reasons for discontinuing topiramate were headache (N=3) and paresthesias (N=2).

293 Because effects of topiramate were not maintained at longer-term follow-up,

294 Sodium valproate, benzodiazepines and topiramate were reported as being the most helpful medic

295 that the clinically available anticonvulsant topiramate, when administered post-insult in vivo, is pr

296 was found that both patient were taking oral Topiramate which had been started 2 weeks before the ons

297 ciations were found for prenatal exposure to topiramate with attention-deficit/hyperactivity disorder

298 of means [RoM], 0.38; 95% CI, 0.18-0.79) and topiramate with vitamin D3 (RoM, 0.44; 95% CI, 0.30-0.65

299 The combination of phentermine and topiramate, with office-based lifestyle interventions, m

300 ypothesis that the combination of MAS-ER and topiramate would be superior to placebo in achieving 3 w